CLIA Kit for Brain Derived Neurotrophic Factor (BDNF)
Neurotrophin; Abrineurin
- Product No.SCA011Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- All
- Human
- Mouse
- Rat
- Cavia
- Rabbit
- Simian
- Caprine
- Ovine
- Equine
- Bovine
- Porcine
- Gallus
- Canine
- Others
- Multi-species
- Pan-species
- Test MethodDouble-antibody Sandwich
- Assay Length2h, 40min
- Detection Range27.4-20,000pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 11.2pg/mL.
- Sample Typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- DownloadInstruction Manual
- UOM48T96T96T*596T*1096T*100
- FOBUS$ 588 For more details, please contact local distributors!US$ 840 For more details, please contact local distributors!US$ 3780 For more details, please contact local distributors!US$ 7140 For more details, please contact local distributors!US$ 58800 For more details, please contact local distributors!
Packages (Simulation)- Packages (Simulation)
- Results demonstration
- Typical Standard Curve
- ISO9001: 2008, ISO13485: 2003 Registered
Specificity of the CLIA Kit for Brain Derived Neurotrophic Factor (BDNF)
This assay has high sensitivity and excellent specificity for detection of Brain Derived Neurotrophic Factor (BDNF).No significant cross-reactivity or interference between Brain Derived Neurotrophic Factor (BDNF) and analogues was observed.
Recovery of the CLIA Kit for Brain Derived Neurotrophic Factor (BDNF)
Matrices listed below were spiked with certain level of recombinant Brain Derived Neurotrophic Factor (BDNF) and the recovery rates were calculated by comparing the measured value to the expected amount of Brain Derived Neurotrophic Factor (BDNF) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 81-91 | 87 |
| EDTA plasma(n=5) | 85-101 | 90 |
| heparin plasma(n=5) | 92-101 | 96 |
Precision of the CLIA Kit for Brain Derived Neurotrophic Factor (BDNF)
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Brain Derived Neurotrophic Factor (BDNF) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Brain Derived Neurotrophic Factor (BDNF) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CV<10%>Inter-Assay: CV<12%>
Linearity of the CLIA Kit for Brain Derived Neurotrophic Factor (BDNF)
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Brain Derived Neurotrophic Factor (BDNF) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 94-102% | 99-105% | 93-105% | 91-103% |
| EDTA plasma(n=5) | 89-97% | 83-95% | 93-105% | 80-97% |
| heparin plasma(n=5) | 91-104% | 86-94% | 79-104% | 98-105% |
Stability of the CLIA Kit for Brain Derived Neurotrophic Factor (BDNF)
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Assay procedure summary of the CLIA Kit for Brain Derived Neurotrophic Factor (BDNF)
1. Prepare all reagents, samples and standards;2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;4. Aspirate and wash 3 times;5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;6. Aspirate and wash 5 times;7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;8. Read RLU value immediately.
Test principle of the CLIA Kit for Brain Derived Neurotrophic Factor (BDNF)
The microplate provided in this kit has been pre-coated with an antibody specific to Brain Derived Neurotrophic Factor (BDNF). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Brain Derived Neurotrophic Factor (BDNF). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Brain Derived Neurotrophic Factor (BDNF) level in the sample or standard.;
GIVEAWAYS
ELISA / CLIA Experiment Service
INCREMENT SERVICES
Single-component Reagents of Assay KitLysis Buffer Specific for ELISA / CLIAQuality Control of ELISA / CLIACLIA Kit Customized ServiceDisease Model Customized ServiceSerums Customized ServiceTGFB1 Activation ReagentReal Time PCR Experimental ServiceStreptavidin
Related products
| Catalog No. | Organism species: Homo sapiens (Human) | Applications (RESEARCH USE ONLY!) |
| RPA011Hu01 | Recombinant Brain Derived Neurotrophic Factor (BDNF) | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA011Hu02 | Recombinant Brain Derived Neurotrophic Factor (BDNF) | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA011Hu61 | Active Brain Derived Neurotrophic Factor (BDNF) | Cell culture; Activity Assays. |
| EPA011Hu61 | Eukaryotic Brain Derived Neurotrophic Factor (BDNF) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA011Hu01 | Polyclonal Antibody to Brain Derived Neurotrophic Factor (BDNF) | WB; IHC; ICC; IP. |
| PAA011Hu06 | Polyclonal Antibody to Brain Derived Neurotrophic Factor (BDNF) | WB; IHC; ICC; IP. |
| LAA011Hu71 | Biotin-Linked Polyclonal Antibody to Brain Derived Neurotrophic Factor (BDNF) | WB; IHC; ICC. |
| LAA011Hu81 | FITC-Linked Polyclonal Antibody to Brain Derived Neurotrophic Factor (BDNF) | WB; IHC; ICC; IF. |
| MAA011Hu22 | Monoclonal Antibody to Brain Derived Neurotrophic Factor (BDNF) | WB; IHC; ICC; IP. |
| SEA011Hu | ELISA Kit for Brain Derived Neurotrophic Factor (BDNF) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA011Hu | CLIA Kit for Brain Derived Neurotrophic Factor (BDNF) | Chemiluminescent immunoassay for Antigen Detection. |
| KSA011Hu01 | ELISA Kit DIY Materials for Brain Derived Neurotrophic Factor (BDNF) | Main materials for "Do It (ELISA Kit) Yourself". |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
请教各位大神，大家知道怎样对外泌体表面蛋白进行定量吗？看有文献用Western，还有裂解外泌体后用BCA进行定量，请问裂解后的外泌体蛋白定量应该是外泌体全部蛋白的吧，应该不只是表面蛋白（CD63这种）吧，还有这个BCA是怎么操作呢？有没有很可靠地能表示外泌体表面蛋白的定量方法？另外，怎么根据外泌体表面蛋白的量来算出外泌体的量呢？还有外泌体文献报道的外泌体浓度为μg/ml,这种浓度是怎样测出来的呢？还有表示外泌体10^9/ml这个测外泌体个数的应该是通过NTA吧？求大神分享外泌体定量的方法？急急急~
小胶质细胞(microglia)是神经胶质细胞的一种，相当于脑和脊髓中的巨噬细胞，是中枢神经系统(CNS)中的第一道也是最主要的一道免疫防线。小胶质细胞大约占大脑中的神经胶质细胞的20%。小胶质细胞不停地清除着中枢神经系统中的损坏的神经，斑块及感染性物质。无数临床上和神经病理学研究表明激活的小胶质细胞在神经退化类疾病的发病机理中起到十分重要的作用，如帕金森病，多发性硬化和阿兹海默症等。但是过多激活或失控的小胶质细胞会引起神经毒性。他们是促炎因子和氧化应激的重要来源，如肿瘤坏死因子（TNF），一氧化氮，白介素等有神经毒性的物质
各位前辈好，科研新手要研究尿外泌体，想了解一下研究尿外泌体比较大咖的相关国内外团队有哪些。今天就要汇报了。还请各位赏脸赐教一些。需要按照国内和国外列成两列。
癌细胞通过血液由起源部位传播扩散到远处器官是癌症相关死亡的主要原因。这个过程并不随机；相反，一些种类的癌症细胞会通过一系列分子程序，优先寻找特定器官，并在该处筑巢。这种寻找目的地的行为涉及到逃避原发肿瘤的癌细胞（有时也被称为“种子”）和目的器官处的微环境（或叫“土壤”）的互动。而Hoshino等人的研究发现，种子在到达之前，能通过名为外泌体的胞外囊泡来影响“土壤”，从而为肿瘤转移做好准备。
越来越多证据显示，原发肿瘤转移之前会有一系列的系统性反应，这些反应甚至促使了癌症的转移。这些反应可能包括：机体血管的复杂变化、凝血和炎症——例如，癌症相关的变化包括细胞种类、可溶性蛋白和血液中外泌体的变化。
Hoshino等人把外泌体定义为小小的，把蛋白质、脂质和核酸由一个细胞运输到另一个细胞的，可以随着血液传播到远端的胞外囊泡。外泌体在癌症研究领域引起了很多人的关注——因为一些细胞外囊泡携带致癌基因，促进癌症的形成和疾病进展。
外囊泡，包括外泌体，在转移微环境形成及为转移做准备过程的几个关键事件中起了重要作用，研究者们对此也研究了好几年。例如，黑色素瘤的小鼠模型中，外泌体和毛细管壁之间的互动引起血管通透性变化，使肿瘤细胞能从血管中逃逸，进入一个新位点。此外，外泌体能把致癌基因MET受体蛋白转移到循环的骨髓细胞中，从而改变其行为，为癌症转移做准备。胰腺癌模型中，血液中的外泌体把转移抑制因子蛋白转移到肝脏的库普弗免疫细胞（Kupffercell）上，引发一连串事件，促进转移微环境的形成。
虽然这些结果表明外泌体促进肿瘤转移，但外泌体是否和如何参与肿瘤的器官特异性转移方面的研究非常匮乏。为研究这一问题，Hoshino等人提出问题：优先转移至肺、肝、脑或骨的癌症细胞是否可能会在转移之前通过外泌体与这些器官进行互动。实验结果正是如此。把癌细胞的外泌体注射到小鼠体内，这些外泌体会滞留在癌细胞倾向于转移的器官中。此外，这些器官特异性的外泌体能与不同的细胞类型互动。例如，靶向肺的外泌体会粘附在肺内的内皮细胞上，而靶向肝脏的外泌体则会进入库普弗免疫细胞。
Hoshino等人把癌细胞的外泌体注入相同的细胞系中，证明了外泌体促进肿瘤的器官特异性转移。然后他们发现了一个有趣的现象——转移到肺部的乳腺癌细胞的外泌体能把另一类通常会转移到骨头的肿瘤细胞重定向到肺部。这一发现进一步证实肿瘤细胞的转移特征并不是自主的，而是由外部因素影响的。
Hoshino等人针对外泌体如何影响器官特异性转移提供了几点线索。他们发现，针对不同器官的外泌体拥有不同的细胞粘附受体蛋白，即细胞表面的整合素（integrin）。不同类型的外泌体会倾向性地进入拥有大量与其表面整合素对应的配体的器官中。例如，αVβ5整合素把外泌体定向到肝脏，而α6β4则定向到肺（图1）。此外，抑制胞外体的表达或整合素的表达，能抑制癌症转移。最后，Hoshino外泌体侵入目的器官时，会引起S100蛋白的合成，从而促进炎症和细胞迁移，并激活Src蛋白——这些都为癌症细胞的转移奠定基础。
这些重要发现扩大我们对肿瘤器官特异性转移的认识。然而，如何把这一认识转化为临床手段还需要更充分的研究。Hoshino等人证实了整合素的表达可以预测转移，指出外泌体整合素用于癌症诊断的潜能。他们的数据还表明，整合素抑制剂可能会减少特定器官癌症的转移。但在许多情况下，晚期癌症会扩散到多个器官，限制了器官特异性转移疗法的应用前景。
需要注意的是，肿瘤转移的分子通路（无论是外泌体依赖和独立的）可能非常多。因此，它们可能受很多相关因素影响：肿瘤细胞中的不同通路的激活、肿瘤中的一个特定分子亚型的出现，以及干预治疗等。例如，乳腺癌分子亚型之间的脑转移发生率不同，致癌蛋白ERBB2型乳腺癌，即使在ERBB2抑制剂有效治疗后，仍更倾向于转移到脑。科学家们不清楚的是，ERBB2抑制剂治疗是否会影响，以及如何影响器官倾向性的外泌体的释放。他们对这一课题的研究怀有极大兴趣。同样，炎症、凝血功能异常和其它癌症相关的生理变化可能会与外泌体的器官定向机制有关，因此在分析转移路径时，必须充分考虑这些因素。因此，不同类型的癌症中外泌体定向特定器官和影响“土壤”的机制还需要更充分的研究。（生物谷：Bioon.com）
此贴是外泌体学习、相关答疑、战友互助、资源交换的专题帖，欢迎各位道友加入，互相交流学习，如有外泌体相关问题请留言，楼主会做解答。
版主yj1984ren留言:
欢迎！
这个PPT是故障的，里面内容不全，大家不要下载，请大家和版主说让他把这篇帖子删除我重新再发
外泌体提取与鉴定.pptx(2895.91k)
exosome，外泌体，是由细胞分泌到外周体液进行细胞间以及细胞与远程组织、器官之间进行信息交流的一种媒介。当前逐渐成为国际研究热点。目前国内刚刚起步，虽然研究成果较国外研究机构尚有不少差距，但已有迎头赶上之势。
外泌体只是胞外囊泡的一种，目前尚未有明确定论胞外囊泡中其它成分的功能。
为了跟随时代科学研究进步的步伐，我建议开通“胞外囊泡及外泌体”讨论区，以促进该领域的充分讨论和合作，弥补当前该领域讨论内容分散，资料不容易汇集等缺点。同时也为广大胞外囊泡及外泌体医学研究者提供一个更好的交流空间。
有没有前辈从事外泌体的研究，想从细胞上清中提取外泌体，但是因为实验室条件的因素，无法超离血清，想请教一下培养细胞的话还有没有什么别的方法？万分感激！！！！！！！！！！！！！！！！
暂无品牌问答
